Antibody Drug Delivery In-Vitro 
Worldwide Clinical Trials
JUNE 21, 2024
This year, Matt Cooper, PhD , our Executive Director, Therapeutic Strategy Lead, Oncology, attended and found the presentations around antibody-drug conjugates (ADCs) and tumor-infiltrating lymphocytes (TILs) to be of great interest to the future of oncology therapeutics.
The Pharma Data
JANUARY 6, 2021
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection. The complete text of the article titled, “Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism,” can be found h e re.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 16, 2021
It has become the de facto standard equipment for high titer transient protein expression platforms used by many leading Chinese antibody drug pharmaceutical companies and IVD (In Vitro Diagnostics) companies since its launch in Oct. for non-viral cell immunotherapeutic drug development. JS Bio’s parent company.
The Pharma Data
MAY 15, 2023
If approved, this would be the third indication for Vabysmo, the first bispecific antibody available for the treatment of retinal conditions that can cause blindness.” 1,2 Vabysmo’s safety profile was consistent with previous trials. Roche’s Chief Medical Officer and Head of Global Product Development. In BALATON, vision gains were +16.9
The Pharma Data
APRIL 12, 2023
4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. Chief Medical Officer and Head of Global Product Development.
Roots Analysis
OCTOBER 22, 2023
In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies.
pharmaphorum
DECEMBER 15, 2022
Oxsonics Therapeutics, which offers an ultrasound-based drug delivery platform, appointed Jérôme Marzinski, a board member at Cimon Medical and former CEO of ophthalmic diagnostic company Visiometrics into its top job. The month of November saw a number of notable hires and personnel moves in biotech and pharma. More CEO shakeups.
Expert insights. Personalized for you.
162 
Let's personalize your content